SGLT2 Inhibition Updates 2021 - SGLT2 Inhibition in Cardiorenal Disease
Published: 20 July 2021
Welcome and Introduction
- Welcome and Introduction
- SGLT2 Inhibitors for Patients with Diabetes and an Increased CV Risk: How The Success Story Started
- SGLT2 Inhibitors: Evolution from Glucose Lowering to Cardiorenal Protection
- SGLT2 Inhibitors in Cardiology Indications: The Data
- SGLT2 Inhibitors in Chronic Kidney Disease: The Data
- Panel Discussion
Organised with scientific co-chairs Stefan Anker and Andrew Coats, this event includes presentations and panel discussions with a host of international thought-leaders.
The SGLT2 Updates 2021 conference SGLT2 Inhibition in Cardiorenal Disease: Translating Evidence into Clinical Practice covers the place of SGLT2 inhibitors in the newly released guidelines of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) as well as their implementation in clinical practice.
In addition to plenary sessions and satellite symposia the conference featured a number of Meet The Expert breakout sessions discussing the implications in treatment of specific patient subgroups including patients with comorbidities. Audience questions were submitted throughout and were addressed by the panel experts.
SGLT2 Inhibition in Cardiorenal Disease
- Prepare cardiologists, nephrologists and endocrinologists to effectively manage patients with heart failure, individually and collaboratively
- Apply findings from clinical trials into clinical practice
- Describe the role of SGLT2 inhibitors in different patient subgroups, including patients with comorbidities
- Evaluate the safety and cardiorenal benefits of glucose-lowering agents
- Implement the new guidelines of the HFA of the ESC in clinical practice
More from this programme
State of the Art 1
SGLT2 Inhibitors in Heart Failure: A Practical Approach
Meet The Expert: Implications for Clinical Practice - Breakout 1
Meet The Expert: Implications for Clinical Practice - Breakout 2
Meet The Expert: Implications for Clinical Practice - Breakout 3
State of the Art 2
SGLT2 Inhibitors for Heart Failure: The New Standard of Care
Meet The Expert: Implications for Clinical Practice - Breakout 4
Meet The Expert: Implications for Clinical Practice - Breakout 5
Meet The Expert: Implications for Clinical Practice - Breakout 6
Professor of Cardiology
Dr Stefan Anker was born in East Berlin, Germany in 1965 and has been a doctor for almost thirty years. In his own words, he “never considered doing anything other than medicine.” He is a prodigious researcher who has published over 950 original papers, reviews and editorials.
Dr Anker has also won a number of awards, including the 2018 Copernicus Prize from the German DFG and Polish FNP. Working with both systems in the United Kingdom and Germany has been enjoyable for him because he loves the freedom that it provides as an academic. He would like to play more tennis or golf if he had the time, and enjoys collecting sculptures; particularly anything “skinny or thin.”
University of Manitoba, Canada
Dr Shelley Zieroth is at SBH Heart Failure and Transplant Clinics and serves as Head of the Medical Heart Failure Program, WRHA Cardiac Sciences Program, and as Associate Professor of the Section of Cardiology at the University of Manitoba, Canada.
Dr Zieroth attended medical school at the University of Manitoba, where she went on to train in internal medicine and cardiology. She completed her postdoctoral clinical fellowship, specializing in advanced heart failure and cardiac transplant, at Toronto General Hospital. Dr Zieroth has lectured internationally on the subject of heart failure.
Dr Shelley Zieroth is an Editorial Board member of Cardiac Failure Review.